Direct improvement of quality of life using a tailored quality of life diagnosis and therapy pathway: randomised trial in 200 women with breast cancer
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Despite thousands of papers, the value of quality of life (QoL) in curing disease remains uncertain. Until now, we lacked tools for the diagnosis and specific treatment of diseased QoL. We approached this problem stepwise by theory building, modelling, an exploratory trial and now a definitive randomised controlled trial (RCT) in breast cancer, whose results we report here. METHODS: In all, 200 representative Bavarian primary breast cancer patients were recruited by five hospitals and treated by 146 care professionals. Patients were randomised to either (1) a novel care pathway including diagnosis of 'diseased' QoL (any QoL measure below 50 points) using a QoL profile and expert report sent to the patient's coordinating practitioner, who arranged QoL therapy consisting of up to five standardised treatments for specific QoL defects or (2) standard postoperative care adhering to the German national guideline for breast cancer. The primary end point was the proportion of patients in each group with diseased QoL 6 months after surgery. Patients were blinded to their allocated group. RESULTS: At 0 and 3 months after surgery, diseased QoL was diagnosed in 70% of patients. The QoL pathway reduced rates of diseased QoL to 56% at 6 months, especially in emotion and coping, compared with 71% in controls (P=0.048). Relative risk reduction was 21% (95% confidence interval (CI): 0-37), absolute risk reduction 15% (95% CI: 0.3-29), number needed to treat (NNT)=7 (95% CI: 3-37). When QoL therapy finished after successful treatment, diseased QoL often returned again, indicating good responsiveness of the QoL pathway. CONCLUSION: A three-component outcome system including clinician-derived objective, patient-reported subjective end points and qualitative analysis of clinical relevance was developed in the last 10 years for cancer as a complex intervention. A separate QoL pathway was implemented for the diagnosis and treatment of diseased QoL and its effectiveness tested in a community-based, pragmatic, definitive RCT. While the pathway was active, it was effective with an NNT of 7.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Some Methods for Strengthening the Common χ 2 Tests
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001616 · Cited by 3,718
Framework for design and evaluation of complex interventions to improve health
Campbell, M. (2000) · BMJ · doi:10.1136/bmj.321.7262.694 · Cited by 3,474
Velikova, G., Booth, L., Smith, A. B., Brown, P. M., Lynch, P., Brown, J. M., & Selby, P. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.078 · Cited by 1,382
Detmar, S. B., Muller, M. J., Schornagel, J. H., Wever, L. D. V., & Aaronson, N. K. (2002) · JAMA · doi:10.1001/jama.288.23.3027 · Cited by 1,011 · cited 2×
“Some fragments of the puzzle were successfully completed in a few randomised trials (Rubenstein et al, 1995; Detmar et al, 2002; Velikova et al, 2004) and systematic reviews.”
BackgroundConfidence intervals for the number needed to treat.
Altman, D. G. (1998) · BMJ · doi:10.1136/bmj.317.7168.1309 · Cited by 938
Multiplicity in randomised trials I: endpoints and treatments
Schulz, K. F., & Grimes, D. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66461-6 · Cited by 366
The clinical significance of quality of life assessments in oncology: a summary for clinicians
Sloan, J. A., Frost, M. H., Berzon, R., Dueck, A., Guyatt, G., Moinpour, C., Sprangers, M., Ferrans, C., Cella, D., & Clinical Significance Consensus Meeting Group (2006) · Supportive Care in Cancer · doi:10.1007/s00520-006-0085-y · Cited by 149 · cited 2×
“We approached this problem stepwise by theory building, modelling, an exploratory trial and now a definitive randomised controlled trial (RCT) in breast cancer, whose results we report here.”
BackgroundMethodFeasibility and Compliance of Automated Measurement of Quality of Life in Oncology Practice
Wright, E. P., Selby, P. J., Crawford, M., Gillibrand, A., Johnston, C., Perren, T. J., Rush, R., Smith, A., Velikova, G., Watson, K., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.044 · Cited by 119
Cited by
Kotronoulas, G., Kearney, N., Maguire, R., Harrow, A., Di Domenico, D., Croy, S., & MacGillivray, S. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.5948 · Cited by 946
Psychological interventions for women with non-metastatic breast cancer
Jassim, G. A., Whitford, D. L., Hickey, A., & Carter, B. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008729.pub2 · Cited by 163
Psychological interventions for women with non-metastatic breast cancer
Jassim, G. A., Doherty, S., Whitford, D. L., & Khashan, A. S. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008729.pub3 · Cited by 58
Möhler, R., Bartoszek, G., & Meyer, G. (2013) · BMC Medical Research Methodology · doi:10.1186/1471-2288-13-125 · Cited by 21
Implementation of a mobile inpatient quality of life (QoL) assessment for oncology nursing
Schuler, M. K., Trautmann, F., Radloff, M., Schmädig, R., Hentschel, L., Eberlein-Gonska, M., Petzold, T., Vetter, H., Oberlack, S., Ehninger, G., et al. (2016) · Supportive Care in Cancer · doi:10.1007/s00520-016-3163-9 · Cited by 10
Metadata
- Authors
- for the Regensburg QoL Study Group, Klinkhammer-Schalke, M., Koller, M., Steinger, B., Ehret, C., Ernst, B., Wyatt, J. C., Hofstädter, F., & Lorenz, W.
- Venue
- British Journal of Cancer
- Published
- 2012-02
- Volume
- 106
- Issue
- 5
- Pages
- 826-838
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2136629791
- Cited by
- 103
- References
- 8
- FWCI
- 3.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.